Literature DB >> 34556483

B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics.

Renaud Felten1,2, Pierre-Marie Duret3, Elodie Bauer4, Nathanael Sedmak5, Julien H Djossou6, Massiva Bensalem1, Marc Ardizzone7, Marion Geoffroy8, Angelique Fan9, Marion Couderc9, Jean Hugues Salmon8,10, Laurent Messer3, Rose-Marie Javier1, Alain Meyer1, Emmanuel Chatelus1, Christelle Sordet1, Luc Pijnenburg1, Jérémy Fort1, Marina Rinagel1, Julia Walther11, Cassandre Fabre11, Laurent Arnaud1, Jean Sibilia1, Nicolas Meyer5, Francis Berenbaum6,12, Isabelle Chary-Valckenaere4, Martin Soubrier9, Jérémie Sellam6,12, Jacques-Eric Gottenberg13,2.   

Abstract

Entities:  

Keywords:  Biological Therapy; Covid-19; Rituximab; Therapeutics

Mesh：

Substances：

Year:  2021        PMID： 34556483     DOI： 10.1136/annrheumdis-2021-220549

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

Authors:  Anne Constanze Regierer; Rebecca Hasseli; Martin Schäfer; Bimba F Hoyer; Andreas Krause; Hanns-Martin Lorenz; Alexander Pfeil; Jutta Richter; Tim Schmeiser; Hendrik Schulze-Koops; Anja Strangfeld; Reinhard E Voll; Christof Specker; Ulf Mueller-Ladner
Journal:  RMD Open       Date:  2021-10

2.  Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab.

Authors:  Renaud Felten; Floriane Gallais; Cédric Schleiss; Emmanuel Chatelus; Rose-Marie Javier; Luc Pijnenburg; Christelle Sordet; Jean Sibilia; Laurent Arnaud; Samira Fafi-Kremer; Jacques-Eric Gottenberg
Journal:  Lancet Rheumatol       Date:  2021-11-08

Review 3.  COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.

Authors:  Rebecca Grainger; Alfred H J Kim; Richard Conway; Jinoos Yazdany; Philip C Robinson
Journal:  Nat Rev Rheumatol       Date:  2022-02-25       Impact factor: 32.286

4.  Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge.

Authors:  Anca Bobirca; Cristina Alexandru; Anca Emanuela Musetescu; Florin Bobirca; Anca Teodora Florescu; Magdalena Constantin; Tiberiu Tebeica; Alesandra Florescu; Sebastian Isac; Mihai Bojinca; Ioan Ancuta
Journal:  Life (Basel)       Date:  2022-07-23

5.  Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study.

Authors:  Gabriel Figueroa-Parra; Emily L Gilbert; Maria O Valenzuela-Almada; Sebastian Vallejo; Matthew R Neville; Naomi J Patel; Claire Cook; Xiaoqing Fu; Ramla Hagi; Gregory C McDermott; Michael A Dilorio; Lucy Masto; Kathleen M M Vanni; Emily Kowalski; Grace Qian; Yuqing Zhang; Zachary S Wallace; Alí Duarte-García; Jeffrey A Sparks
Journal:  Lancet Rheumatol       Date:  2022-09-13

6.  Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients.

Authors:  Rohan Ameratunga; See-Tarn Woon; Richard Steele; Klaus Lehnert; Euphemia Leung; Emily S J Edwards; Anna E S Brooks
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.